said their Erbitux colon cancer drug helped patients survive longer in one late-stage clinical trial but not in another.
The New York-based drug giant said one trial compared Erbitux plus best supportive care to best supportive care alone in 572 patients with metastatic colorectal cancer whose disease was refractory to all available chemotherapy.
In that phase III trial, the Erbitux group showed a statistically significant improvement in overall survival.
A second phase III study compared irinotecan to irinotecan plus Erbitux in approximately 1,300 patients whose disease was not responding to first-line oxaliplatin-based chemotherapy.
In that study, the Erbitux group's overall survival wasn't improved enough to meet the study's endpoint.